Eyepoint Pharmaceuticals (EYPT) Competitors $11.83 +0.23 (+1.98%) Closing price 04:00 PM EasternExtended Trading$11.87 +0.04 (+0.35%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EYPT vs. TXG, TRNS, ALNT, AEHR, CTKB, LAB, SENS, FEIM, MASS, and QSIShould you be buying Eyepoint Pharmaceuticals stock or one of its competitors? The main competitors of Eyepoint Pharmaceuticals include 10x Genomics (TXG), Transcat (TRNS), Allient (ALNT), Aehr Test Systems (AEHR), Cytek Biosciences (CTKB), Standard BioTools (LAB), Senseonics (SENS), Frequency Electronics (FEIM), 908 Devices (MASS), and Quantum-Si (QSI). These companies are all part of the "measuring and control equipment" industry. Eyepoint Pharmaceuticals vs. Its Competitors 10x Genomics Transcat Allient Aehr Test Systems Cytek Biosciences Standard BioTools Senseonics Frequency Electronics 908 Devices Quantum-Si Eyepoint Pharmaceuticals (NASDAQ:EYPT) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk. Do analysts rate EYPT or TXG? Eyepoint Pharmaceuticals currently has a consensus target price of $25.38, indicating a potential upside of 114.50%. 10x Genomics has a consensus target price of $13.54, indicating a potential downside of 5.30%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Eyepoint Pharmaceuticals is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eyepoint Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.0010x Genomics 1 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.38 Do insiders and institutionals have more ownership in EYPT or TXG? 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 9.4% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, EYPT or TXG? Eyepoint Pharmaceuticals has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Which has higher valuation & earnings, EYPT or TXG? Eyepoint Pharmaceuticals has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEyepoint Pharmaceuticals$43.27M18.85-$130.87M-$2.68-4.4110x Genomics$610.78M2.91-$182.63M-$0.70-20.43 Is EYPT or TXG more profitable? 10x Genomics has a net margin of -13.13% compared to Eyepoint Pharmaceuticals' net margin of -337.93%. 10x Genomics' return on equity of -12.88% beat Eyepoint Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eyepoint Pharmaceuticals-337.93% -63.80% -50.72% 10x Genomics -13.13%-12.88%-10.03% Does the media favor EYPT or TXG? In the previous week, 10x Genomics had 8 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 11 mentions for 10x Genomics and 3 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.87 beat 10x Genomics' score of 0.61 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 3 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryEyepoint Pharmaceuticals and 10x Genomics tied by winning 8 of the 16 factors compared between the two stocks. Get Eyepoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EYPT vs. The Competition Export to ExcelMetricEyepoint PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$799.56M$3.11B$5.76B$9.59BDividend YieldN/A2.23%4.41%4.09%P/E Ratio-4.417.3322.4021.92Price / Sales18.85398.09472.14121.31Price / CashN/A43.1937.7358.48Price / Book3.318.129.536.61Net Income-$130.87M-$54.72M$3.26B$265.56M7 Day Performance6.67%2.62%2.11%1.98%1 Month Performance13.21%7.63%5.12%1.33%1 Year Performance31.44%13.11%31.25%21.15% Eyepoint Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EYPTEyepoint Pharmaceuticals1.9403 of 5 stars$11.83+2.0%$25.38+114.5%+28.2%$799.56M$43.27M-4.41120Positive NewsTXG10x Genomics3.7881 of 5 stars$13.46+0.7%$13.54+0.6%-43.1%$1.66B$610.78M-19.231,240TRNSTranscat2.878 of 5 stars$82.24+0.9%$112.20+36.4%-29.7%$759.88M$288.14M57.511,245Positive NewsAnalyst ForecastALNTAllient3.2267 of 5 stars$44.56+2.4%$35.00-21.5%+110.0%$737.53M$529.97M51.812,525News CoverageAnalyst RevisionAEHRAehr Test Systems1.9169 of 5 stars$19.39+5.9%N/A+22.0%$547.74M$58.97M-149.1490Positive NewsOptions VolumeCTKBCytek Biosciences3.597 of 5 stars$4.06+1.2%$5.60+37.9%-25.5%$510.17M$200.45M-81.20500LABStandard BioTools2.5672 of 5 stars$1.27+3.3%$1.55+22.0%-38.1%$467.18M$174.43M-3.97620Positive NewsSENSSenseonics2.3638 of 5 stars$0.47-0.7%$1.55+230.1%+6.2%$382.49M$25.47M-3.6190News CoveragePositive NewsFEIMFrequency Electronics1.3926 of 5 stars$28.38-7.8%N/A+110.5%$299.33M$69.81M11.49200MASS908 Devices2.7489 of 5 stars$6.27-5.4%$8.00+27.6%+42.7%$237.76M$59.63M-11.6160QSIQuantum-Si2.468 of 5 stars$1.09-0.9%$3.48+218.8%+9.9%$222.74M$3.06M-1.60150 Related Companies and Tools Related Companies TXG Alternatives TRNS Alternatives ALNT Alternatives AEHR Alternatives CTKB Alternatives LAB Alternatives SENS Alternatives FEIM Alternatives MASS Alternatives QSI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EYPT) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyepoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access